Page last updated: 2024-10-27

vanoxerine and Liver Neoplasms

vanoxerine has been researched along with Liver Neoplasms in 1 studies

vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.

Liver Neoplasms: Tumors or cancer of the LIVER.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zhu, Y1
Ke, KB1
Xia, ZK1
Li, HJ1
Su, R1
Dong, C1
Zhou, FM1
Wang, L1
Chen, R1
Wu, SG1
Zhao, H1
Gu, P1
Leung, KS1
Wong, MH1
Lu, G1
Zhang, JY1
Jiang, BH1
Qiu, JG1
Shi, XN1
Lin, MC1

Other Studies

1 other study available for vanoxerine and Liver Neoplasms

ArticleYear
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Molecular medicine (Cambridge, Mass.), 2021, 02-12, Volume: 27, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Depe

2021
chemdatabank.com